

Biotech Capital.

Biotech Capital (BTC) - ASX Announcement

21 November 2016

STRATEGIC ALLIANCE WITH INDUSTRY EXPERT IN SAN DIEGO, USA

Biotech Capital Limited (ASX:BTC) announced today that it has established a working partnership with Dr. John Chiplin, Managing Director of Newstar Ventures, located in San Diego, USA. (www.newstarventures.com)

With increased lead generation and greater awareness of Biotech Capital's services, it is expected the partnership will identify and facilitate a range of new business opportunities with biotech and medtech companies on both sides of the Pacific.

John holds Pharmacy and Doctoral degrees from the University of Nottingham and he brings significant international experience in the life science and technology industries. He currently serves on the boards of Adalta, Batu Biologics, Benitec Biopharma, The Coma Research Institute, Cynata Therapeutics, Prophecy, Scancell Holdings, ScienceMedia, and Sienna Cancer Diagnostics. More recently, he has played a central role in a number of life science transactions, IPO's and capital raisings.

Biointelect (www.biointelect.com) and Bio101 (www.bio101.com), which are wholly owned subsidiaries of Biotech Capital Limited, currently provide a range of professional services to high-growth biotech, medtech and pharmaceutical companies across the globe. Approximately half the group's existing revenues are from international clients and the group is actively seeking to build on this.

Biotech Capital's Chairman Dr. Richard Treagus commented; "We are delighted to be working with John and we are excited by the prospect of combining our expertise, industry networks and organizational capabilities. This represents a very practical step towards building an even greater level of collaboration between Australian and USA life science companies."

Dr. Chiplin commented "There is clear synergy and complementarity between the significant expertise of both Australian and US Life Science companies. The goal of the partnership is to expand, enhance, and develop these relationships on a trans-Pacific basis"

About Biotech Capital Limited

Biotech Capital is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company's strategy is to make active investments in life science businesses and late-stage product development opportunities that will benefit from greater access to development capital. The company has the longer-term objective of building a group of complimentary businesses that are entrepreneurial, innovative, globally focused and when operating together have the ability to generate better health outcomes and add value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares.

Biotech Capital.

Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.

For more information, please contact:

Dr. Richard Treagus, Chairman
rtreagus@biotechcapital.com.au

+61 417 520 509